Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer
Completed · Phase 3
Conditions studied: Metastatic Breast Cancer
In brief
The primary objective of this study is to assess and compare the efficacy and safety of sacituzumab govitecan-hzi versus treatment of physician's choice (TPC) in participants with hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2-) negative metastatic breast cancer (MBC).
Key facts
- Study ID
- NCT03901339
- Run by
- Gilead Sciences
- People needed
- 543
- Starts
- 2019-05-08
- Expected to finish
- 2023-10-20
- Last updated by the study team
- 2024-10-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Arizona Oncology Associates, PC — Tucson, Arizona, United States
- Highlands Oncology Group — Fayetteville, Arkansas, United States
- University of California, San Diego Moores Cancer Center — La Jolla, California, United States
- Los Angeles Hematology Oncology Medical Group — Los Angeles, California, United States
- UCLA Department of Medicine - Hematology/Oncology — Los Angeles, California, United States
- University of California, Irvine Medical Center-Chao Family Comprehensive Cancer Center — Orange, California, United States
- Southern California Permanente Medical Group — San Diego, California, United States
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States
- Rocky Mountain Cancer Centers — Aurora, Colorado, United States
- University of Colorado — Aurora, Colorado, United States
- Yale University Cancer Center — New Haven, Connecticut, United States
- Georgetown University Medical Center — Washington D.C., District of Columbia, United States
- University of Miami - Sylvester Comprehensive Cancer Center — Miami, Florida, United States
- Miami Cancer Institute — Miami, Florida, United States
- Orlando Health, Inc. — Orlando, Florida, United States
- Moffitt Cancer Center — Tampa, Florida, United States
- Emory University - Winship Cancer Institute — Atlanta, Georgia, United States
- Northside Hospital, Inc. — Atlanta, Georgia, United States
- University of Chicago Medical Center — Chicago, Illinois, United States
- The University of Kansas Cancer Center — Westwood, Kansas, United States
- James Graham Brown Cancer Center — Louisville, Kentucky, United States
- Mercy Medical Center, Medical Oncology & Hematology — Baltimore, Maryland, United States
- Maryland Oncology Hematology, P.A. — Rockville, Maryland, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- HonorHealth Research Institute — Avondale, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.